Husain M, Birkenfeld AL, Donsmark M et al (2019) Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes
Como sabemos, diabetes e obesidade so doenas que costumam andar juntas, ento a terapia com medicamentos anlogos ao GLP-1 um importante aliado
(2015) documented that oral glutathione at 250-1000 mg daily for 6 months did increase blood, erythrocyte, and lymphocyte glutathione levels, though the magnitude of increase was smaller than injectable or IV routes (Richie et al., 2015)
Contrave vs Qsymia for GLP-1 intolerance For patients who cannot tolerate GLP-1 receptor agonists or have a history of pancreatitis, Contrave and Qsymia are effective alternative options
People who have had gastric surgery or part of their bowel removed may be at risk for developing a B12 deficiency
Biomarkers That Strengthen Medical Necessity Documentation Beyond HbA1c, specific biomarkers indicate cardiometabolic dysfunction and support insurance approval arguments